Real-world treatment patterns and outcomes of patients with HER2+ advanced breast cancer

This thesis focuses on patients with metastatic breast cancer with HER2+ receptor, data was collected on patient and disease characteristics, treatment pattern, and survival. This thesis showed that the majority of patients with HER2+ metastatic breast cancer are treated with HER2-targeted therapy. There were significant differences between treatment patterns in patients with hormone-positive and negative disease. Patients with hormone-negative and HER2+ metastatic breast cancer were more often treated with HER2-targeted therapy and had a higher use of new HER2-targeted therapies such as pertuzumab and T-DM1. The implantation of HER2-targeted treatment has improved the overall survival of patients, especially those with hormone negative/HER2+ subtype.